Peptide Initiative

Injection guide · Mitochondrial

How to inject SS-31 (Elamipretide)

A mitochondria-targeting tetrapeptide that binds cardiolipin in the inner mitochondrial membrane. The FDA approved it in September 2025 as FORZINITY, to improve muscle strength in Barth syndrome ; phase 3 trials in primary mitochondrial myopathy and in dry age-related macular degeneration missed their primary endpoints .

SubcutaneousRoute
3 recommendedSites
Once dailyFrequency

01 · Preparation

What you'll need

  • Nothing, for the approved product — FORZINITY is supplied as a ready-to-use 80 mg/mL solution and is not reconstituted [8]
  • The steps below apply only to research-grade lyophilised SS-31, which has no approved label behind it
  • Bacteriostatic water
  • Insulin syringes (29-31 gauge)
  • Alcohol swabs

Pro tip

Prepare all supplies on a clean surface before you begin. Having everything ready makes the process smoother and more sterile.

02 · Mixing

Reconstitution steps

  1. Wash your hands thoroughly with soap and water. Gather all supplies on a clean, flat surface.
  2. Remove the plastic cap from the peptide vial and wipe the rubber stopper with an alcohol swab. Let it air dry.
  3. Draw the appropriate amount of bacteriostatic water into a sterile syringe.
  4. Insert the needle into the vial at an angle, aiming at the inside wall of the vial. Slowly push the plunger to let the water trickle down the glass wall -- do NOT squirt directly onto the powder.
  5. Once all water is added, gently swirl the vial in a slow circular motion. Never shake the vial, as this can damage the peptide bonds.
  6. Continue swirling until the powder is completely dissolved and the solution is clear. If particles remain, let the vial sit for a few minutes and swirl again.
  7. Label the vial with the date of reconstitution, the peptide name, and the concentration (e.g. 250mcg per 0.1mL).

Example calculation

FORZINITY needs no calculation: the vial holds 80 mg/mL, so a 40 mg dose is 0.5 mL . For research-grade lyophilised powder, a 50 mg vial reconstituted with 2.5 mL of bacteriostatic water gives 20 mg/mL, so 2 mL (200 units on an insulin syringe) is the 40 mg dose.

Dose calculation

The dose is 40 mg once daily in both cases [8]. From the 80 mg/mL approved solution that is 0.5 mL. From research-grade powder at 20 mg/mL it is 2 mL. The reduced renal dose of 20 mg is 0.25 mL of the approved solution, or 1 mL at 20 mg/mL [8].

Pro tip

Always add the bacteriostatic water slowly, letting it run down the side of the vial. Never shake the vial -- swirl gently to avoid damaging the peptide.

03 · Location

Choosing your injection site

  • Site 01AbdomenPinch the skin 2 inches from navel. Avoid the area directly around the belly button. Rotate between left and right sides.
  • Site 02Outer ThighMiddle third of the outer thigh. Keep at least 4 inches above the knee and below the hip. Alternate legs each injection.
  • Site 03Upper ArmBack or outer area of the upper arm. This site may require assistance from another person for proper technique.

Rotate between 3 sites to prevent tissue buildup and ensure consistent absorption.

Pro tip

Rotate your injection sites with each dose to prevent lipohypertrophy (buildup of fatty tissue). Keep a simple log of where you last injected.

04 · Step by step

Injection technique

  1. Wash your hands thoroughly with soap and water
  2. Clean the injection site with an alcohol swab and let it air dry completely
  3. Pinch about an inch of skin to create a fold of fatty tissue
  4. Insert the needle at a 45-90 degree angle (45 if lean, 90 if you have more subcutaneous tissue)
  5. Inject the solution slowly and steadily
  6. Wait 5-10 seconds before withdrawing the needle
  7. Apply light pressure with a clean swab if needed—do not rub

Pro tip

This peptide uses subcutaneous injection (just under the skin)—the standard method used in clinical trials with approximately 92% bioavailability. Inject at a 45-90 degree angle into pinched skin. Aspirate before injecting to ensure you haven't hit a blood vessel.

05 · Timing

Your schedule

How often

Once daily

Best time

The label sets no time of day — one injection daily, at a consistent time . The morning preference previously published here had no source behind it; trials dosed once daily without a specified time .

Dose levels, food and stacking notes and a sample day are on the SS-31 (Elamipretide) dosing protocol.

06 · Preservation

Proper storage

Before mixing

The approved product, FORZINITY, is a ready-to-use solution — 280 mg in 3.5 mL (80 mg/mL) in single-patient vials, four to a carton. It needs no reconstitution. Store it refrigerated at 2-8°C and do not freeze it [8]. Research-grade SS-31 is sold instead as a lyophilised powder; keep that refrigerated at 2-8°C in its sealed vial away from light.

After mixing

Once a FORZINITY vial has been opened, it can be kept refrigerated at 2-8°C or at room temperature between 20-25°C, and must be discarded 8 days after first opening [8]. Reconstituted research-grade powder is a different product with no label behind it; refrigerate it, never freeze it, and protect it from light.

Shelf life after mixing

28 days

Signs of degradation

Discard the vial immediately if you notice any of these:

  • Cloudiness or haze — the label describes the solution as clear and colourless to yellow [8]
  • Visible particles
  • Any colour beyond the clear-to-yellow range the label describes [8]

07 · Important

Safety reminders

When to stop

  • Any sign of a hypersensitivity reaction — skin or respiratory. The label directs discontinuation for a severe reaction and serious hypersensitivity is its only contraindication [8]
  • An injection-site reaction that spreads, worsens, or shows signs of infection. These drove discontinuation in 7.3% of treated participants in phase 3 against 1.8% on placebo [13]
  • Your eGFR falling below 30 mL/min — the label halves the dose rather than stopping, but it needs a prescriber's decision [8]
  • Your prescriber advises discontinuation

Elamipretide is FDA-approved only to improve muscle strength in Barth syndrome, in patients weighing at least 30 kg, and that approval is an accelerated one pending a confirmatory trial [8][9]. Every other use is investigational. It is a prescription injectable — decisions about starting, stopping or adjusting belong with a prescriber.

Clean technique checklist

  • Wash hands thoroughly with soap and water before handling supplies
  • Swab vial tops and injection site with alcohol and let dry
  • Never touch the needle tip or allow it to contact non-sterile surfaces
  • Use a new syringe and needle for each injection
  • Dispose of used sharps in a proper sharps container
  • Store reconstituted peptides according to the storage instructions above

Continue

This guide is for informational purposes only and is not medical advice. Always consult with a qualified healthcare provider before starting any peptide protocol. Individual responses may vary.